HRP20210243T1 - Hiperbulirajući sojevi bakterije shigella - Google Patents

Hiperbulirajući sojevi bakterije shigella Download PDF

Info

Publication number
HRP20210243T1
HRP20210243T1 HRP20210243TT HRP20210243T HRP20210243T1 HR P20210243 T1 HRP20210243 T1 HR P20210243T1 HR P20210243T T HRP20210243T T HR P20210243TT HR P20210243 T HRP20210243 T HR P20210243T HR P20210243 T1 HRP20210243 T1 HR P20210243T1
Authority
HR
Croatia
Prior art keywords
shigella
strain
bacterium
bullae
bacteria
Prior art date
Application number
HRP20210243TT
Other languages
English (en)
Inventor
Christiane Gerke
Francesco Berlanda Scorza
Allan Saul
Luana Maggiore
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of HRP20210243T1 publication Critical patent/HRP20210243T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (16)

1. Soj bakterije Shigella koji ne eksprimira funkcionalan enzim HtrB, naznačen time što soj bakterije Shigella eksprimira najviše 4 od proteina TolA, TolB, TolQ, TolR i Pal.
2. Soj bakterije Shigella u skladu s patentnim zahtjevom 1, naznačen time što je htrB izbačen.
3. Soj bakterije Shigella u skladu s patentnim zahtjevom 1 ili 2, naznačen time što ne eksprimira protein TolR.
4. Soj bakterije Shigella u skladu s patentnim zahtjevom 2 ili 3, naznačen time što bakterija eksprimira 4 od proteina, no ne i TolR.
5. Soj bakterije Shigella u skladu s bilo kojim od patentnim zahtjevima 1-4, naznačen time što je soj ΔtolR bakterije Shigella.
6. Soj bakterije Shigella u skladu s bilo kojim od patentnim zahtjevima 1-5, naznačen time što bakterija ne eksprimira nativni Shigella lipopolisaharid.
7. Soj bakterije Shigella u skladu s patentnim zahtjevom 6, naznačen time što bakterija ne eksprimira nativni Shigella antigen O.
8. Soj bakterije Shigella u skladu s patentnim zahtjevom 1-7, naznačen time što je soj soj ΔtolRΔgalU.
9. Soj bakterije Shigella u skladu s bilo kojim od patentnim zahtjevima 1-8, naznačen time što je gen stxA i/ili gen stxB inaktiviran.
10. Postupak priprave bula iz bakterije Shigella, naznačen time što se sastoji u koraku izdvajanja bula iz medija za uzgoj koji sadrži bakteriju iz roda Shigella koja ne eksprimira funkcionalan enzim HtrB, koju se uzgaja u uvjetima koji omogućuju otpuštanje bula iz bakterija u medij.
11. Postupak u skladu s patentnim zahtjevom 10, naznačen time što se bakterije uzgaja u uvjetima s ograničenom količinom željeza.
12. Bula, naznačena time što je izolirana bula ili bula koju se može dobiti iz bakterije Shigella koja ne eksprimira funkcionalan enzim HtrB.
13. Pripravak, naznačen time što sadrži bule koje se, tijekom uzgoja soja bakterije Shigella u skladu s bilo kojim od patentnim zahtjevima 1 do 9 ili kojeg se može dobiti postupkom u skladu s patentnim zahtjevom 10 ili 11, otpušta u medij za uzgoj.
14. Pripravak u skladu s patentnim zahtjevom 13, naznačen time što ne sadrži žive i/ili cijele bakterije.
15. Pripravak, naznačen time što sadrži bule, gdje se bule može dobiti postupkom u skladu s patentnim zahtjevima 10 ili 11, ili gdje su bule prisutne u filtratu kojeg se može dobiti filtriranjem kroz 0,22 mikrometarski filtar medija za uzgoj u kojem je uzgajan soj bakterije Shigella u skladu s bilo kojim od patentnim zahtjevima 1 do 9.
16. Medij za uzgoj koji sadrži soj bakterije Shigella u skladu s patentnim zahtjevima 1 do 9, ili kojeg se može dobiti postupkom u skladu s patentnim zahtjevom 10, naznačen time što se bakterije uzgaja u uvjetima koji omogućuju otpuštanje bula iz bakterija u medij.
HRP20210243TT 2009-09-28 2021-02-11 Hiperbulirajući sojevi bakterije shigella HRP20210243T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0917002.8A GB0917002D0 (en) 2009-09-28 2009-09-28 Improved shigella blebs
EP17168855.9A EP3279313B1 (en) 2009-09-28 2010-09-28 Hyperblebbing shigella strains

Publications (1)

Publication Number Publication Date
HRP20210243T1 true HRP20210243T1 (hr) 2021-04-02

Family

ID=41350492

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20170845TT HRP20170845T1 (hr) 2009-09-28 2017-06-02 Hiperbulirajući sojevi bakterije shigella
HRP20210243TT HRP20210243T1 (hr) 2009-09-28 2021-02-11 Hiperbulirajući sojevi bakterije shigella

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20170845TT HRP20170845T1 (hr) 2009-09-28 2017-06-02 Hiperbulirajući sojevi bakterije shigella

Country Status (21)

Country Link
US (2) US20130052227A1 (hr)
EP (2) EP3279313B1 (hr)
JP (3) JP2013505716A (hr)
KR (1) KR101786025B1 (hr)
CN (2) CN102906245B (hr)
AU (1) AU2010299577B2 (hr)
BR (1) BR112012006912A8 (hr)
CA (1) CA2775642C (hr)
CY (2) CY1118970T1 (hr)
DK (2) DK3279313T3 (hr)
ES (2) ES2846901T3 (hr)
GB (1) GB0917002D0 (hr)
HR (2) HRP20170845T1 (hr)
HU (1) HUE053188T2 (hr)
LT (2) LT3279313T (hr)
NZ (1) NZ599598A (hr)
PL (2) PL2483389T3 (hr)
PT (2) PT3279313T (hr)
SI (2) SI3279313T1 (hr)
WO (1) WO2011036564A2 (hr)
ZA (1) ZA201202934B (hr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2014076714A2 (en) * 2012-11-19 2014-05-22 Indian Council Of Medical Research Novel immunogenic antigens of shigella
US9636390B2 (en) 2012-11-19 2017-05-02 Indian Council Of Medical Research Immunogenic antigens of shigella
US10376571B2 (en) * 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
CN104974946B (zh) * 2014-04-08 2019-01-11 中国科学院天津工业生物技术研究所 耐高渗透压的重组大肠杆菌及其应用
CL2014001126A1 (es) * 2014-04-29 2014-08-29 Univ Chile Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
WO2016202872A1 (en) 2015-06-16 2016-12-22 Glaxosmithkline Biologicals Sa Immunogenic compositions
CN105647892A (zh) * 2016-03-04 2016-06-08 江南大学 一种D-丙氨酰-D-丙氨酸羧肽酶dacA基因及应用
CN105647893A (zh) * 2016-03-04 2016-06-08 江南大学 一种D-丙氨酰-D-丙氨酸羧肽酶dacD基因及应用
KR20230070521A (ko) 2016-05-03 2023-05-23 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
US20170360881A1 (en) * 2016-06-17 2017-12-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2019163785A1 (ja) * 2018-02-20 2019-08-29 株式会社山田養蜂場本社 膜小胞組成物の製造方法
EP3827085A1 (de) * 2018-07-24 2021-06-02 Wacker Chemie AG Neue bakterielle lpp-mutante und deren verwendung zur sekretorischen herstellung von rekombinanten proteinen
CN111363018B (zh) * 2020-03-26 2021-10-01 廊坊梅花生物技术开发有限公司 重组菌株及其在l-色氨酸制备中的应用
WO2022133289A2 (en) * 2020-12-18 2022-06-23 Codexis, Inc. Engineered uridine phosphorylase variant enzymes
GB202112149D0 (en) 2021-08-24 2021-10-06 Glaxosmithkline Biologicals Sa Shigellla vaccine
CN113897324B (zh) * 2021-10-13 2023-07-28 云南师范大学 一种用作抗锰剂的JcVIPP1重组大肠杆菌及其构建方法
GB202118913D0 (en) 2021-12-23 2022-02-09 Glaxosmithkline Biologicals Sa Method for preparing outer membrane vesicles
CN116855471B (zh) * 2023-09-04 2023-11-28 江苏申基生物科技有限公司 一种嘌呤核苷磷酸化酶突变体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5679564A (en) 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
AU759391B2 (en) 1998-02-12 2003-04-10 Wyeth Holdings Corporation Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
WO2001025254A2 (en) * 1999-10-04 2001-04-12 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
EP1322656B1 (en) 2000-09-26 2008-01-16 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
KR101239242B1 (ko) 2002-08-02 2013-03-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원 조합물을 포함하는 나이세리아 백신 조성물
JP4676426B2 (ja) 2003-03-24 2011-04-27 インターツェル・アクチェンゲゼルシャフト 改良型ワクチン
NZ550152A (en) 2004-04-05 2009-04-30 Pfizer Prod Inc Microfluidized oil-in-water emulsions and vaccine compositions
AU2012207041A1 (en) 2005-02-18 2012-08-16 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated Escherichia Coli
NZ560929A (en) 2005-02-18 2009-12-24 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion

Also Published As

Publication number Publication date
EP3279313B1 (en) 2020-11-25
JP7023248B2 (ja) 2022-02-21
KR101786025B1 (ko) 2017-10-18
CA2775642C (en) 2022-09-06
BR112012006912A2 (pt) 2016-11-22
PT3279313T (pt) 2021-01-13
US20160289632A1 (en) 2016-10-06
JP2016105736A (ja) 2016-06-16
SI3279313T1 (sl) 2021-02-26
BR112012006912A8 (pt) 2017-07-11
LT2483389T (lt) 2017-07-25
JP2013505716A (ja) 2013-02-21
CA2775642A1 (en) 2011-03-31
SI2483389T1 (sl) 2017-08-31
AU2010299577B2 (en) 2015-09-03
HUE053188T2 (hu) 2021-06-28
PL2483389T3 (pl) 2017-09-29
EP3279313A3 (en) 2018-03-21
LT3279313T (lt) 2021-03-25
EP2483389A2 (en) 2012-08-08
PT2483389T (pt) 2017-07-24
ES2846901T3 (es) 2021-07-30
DK3279313T3 (da) 2021-01-25
AU2010299577A1 (en) 2012-05-24
WO2011036564A2 (en) 2011-03-31
WO2011036564A3 (en) 2011-08-04
ES2632747T3 (es) 2017-09-15
GB0917002D0 (en) 2009-11-11
PL3279313T3 (pl) 2021-05-31
US11339367B2 (en) 2022-05-24
HRP20170845T1 (hr) 2017-08-11
EP3279313A2 (en) 2018-02-07
DK2483389T3 (en) 2017-07-10
US20130052227A1 (en) 2013-02-28
NZ599598A (en) 2013-08-30
CY1118970T1 (el) 2018-01-10
KR20120106729A (ko) 2012-09-26
CY1123774T1 (el) 2022-05-27
CN102906245A (zh) 2013-01-30
CN102906245B (zh) 2017-08-18
EP2483389B1 (en) 2017-05-03
JP2019068864A (ja) 2019-05-09
ZA201202934B (en) 2012-12-27
CN107475168A (zh) 2017-12-15

Similar Documents

Publication Publication Date Title
HRP20210243T1 (hr) Hiperbulirajući sojevi bakterije shigella
NZ627915A (en) Probiotic derived non-viable material for infection prevention and treatment
NZ596880A (en) Production of polio virus at high titers for vaccine production
RU2014143979A (ru) Пригодные для использования в пищу бактерии lactobacillus rhamnosus
WO2015052350A3 (en) Live attenuated vaccines
DK1201749T3 (da) Fremgangsmåde til fremstilling af humane bruskimplantater ved hjælp af in vitro dyrkede chondrocytter
RU2006113181A (ru) Способ приготовления кваса
NZ587023A (en) Composition comprising protein and disperse fat
JP2017046687A5 (hr)
WO2009103065A3 (en) Compositions and methods for production of biofuels
WO2014154787A3 (fr) Procédé d'enrichissement en protéines de la biomasse de microalgues
MX2021016017A (es) Metodos de extraccion de proteina y procesamiento corriente abajo de euglena.
MY166220A (en) Rabies virus like particle production in plants
MX2016000725A (es) Metodo para optimizar la eficiencia de la produccion, la calidad organoleptica y la estabilidad con el transcurso del tiempo de una biomasa microalgacea rica en proteinas.
EP3321358A3 (en) Rotavirus-like particle production in plants
WO2017213469A3 (ko) 남조류 스피룰리나 추출물을 함유하는 세포 배양액, 이의 제조방법, 및 이를 이용한 세포의 배양방법
JP2010148517A5 (hr)
ZA202003831B (en) Modified norovirus vp1 proteins and vlps comprising modified norovirus vp1 proteins
SG10201810846WA (en) Cold-adapted-viral-attenuation (cava) and novel attenuated poliovirus strains
WO2019204494A3 (en) Date palm medium compositions and methods
WO2019210887A3 (zh) 一种3D悬浮诱导iPS细胞生成自体黑素细胞的方法及应用
CN102839157A (zh) 稳定共表达hST3GalIV和β1-4GalT1的MDCK细胞系及构建方法和应用
West et al. Gall structure and specificity in Bostrychia culture isolates (Rhodomelaceae, Rhodophyta)
WO2008066774A3 (en) INTERFERON-β PRODUCTION MODULATING LISTERIA STRAINS AND METHODS FOR USING SAME
CN109689868A8 (zh) 用于生产疫苗的化学限定无血清培养基中的mdck悬浮细胞系